In the past decade, advances in epidermal growth factor receptor (EGFR) therapy [2] and anaplastic lymphoma kinase (ALK) therapy [3] have remarkably improved the survival of EGFR positive and ALK positive lung cancer patients. The gene discussed is EGFR; the disease is lung carcinoma.